The Prognostic Significance of KIAA1522 Expression in Non-Small-Cell Lung Cancer Patients.

Autor:	Özdede M; Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, TUR., Taban H; Medical Oncology, Hacettepe University Faculty of Medicine, Ankara, TUR., Akman O; Pathology, Hacettepe University Faculty of Medicine, Ankara, TUR., Önder S; Pathology, Hacettepe University Faculty of Medicine, Ankara, TUR., Kılıçkap S; Medical Oncology, Hacettepe University Faculty of Medicine, Ankara, TUR.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2023 Aug 24; Vol. 15 (8), pp. e44016. Date of Electronic Publication: 2023 Aug 24 (Print Publication: 2023).
DOI:	10.7759/cureus.44016
Abstrakt:	The majority of lung cancers belong to the non-small-cell lung cancer (NSCLC) category, which is linked to a high mortality rate despite significant progress in diagnosis and treatment. Therefore, there is a need for novel prognostic NSCLC biomarkers to improve prognosis which currently remains poor. Recent studies and analyses of gene expression data of NSCLC revealed that high expression of KIAA1522 was significantly associated with poor prognosis and decreased overall survival. We identified 98 patients who underwent radical curative surgical resections or metastasectomy for pulmonary adenocarcinoma and squamous cell carcinoma at our institution or the pathological diagnosis confirmed by our pathologists. Following the latest data, we utilized immunohistochemistry to assess the expression of KIAA1522 and investigated its association with various clinic-demographic parameters, pathological stages, recurrence rates, overall survival, and disease-free survival in patients who achieved complete remission. Notably, there were no significant differences in the expression profiles of KIAA1522 between adenocarcinoma and squamous cell carcinoma samples (p=0.6). Survival analysis was conducted using log-rank tests and a multivariate Cox proportional hazard model. Of the 98 samples, 54 (55.1%) exhibited high expression of KIAA1522, and patients with high KIAA1522 expression had a significantly shorter overall survival than the low-expression group (p=0.01). Multivariate Cox proportional hazard models in which metastatic patients were included revealed that along with older age, higher TNM stage (tumor, node, metastasis system), and Eastern Cooperative Oncology Group (ECOG) performance status, high expression of KIAA1522 served as an independent prognostic factor. A high expression profile was not significantly associated with relapses in those whose complete remission had been achieved. Still, those patients with high expression of KIAA1522 tended to exhibit a shorter disease-free survival rate. In conclusion, our findings suggest that KIAA1522 expression is an independent factor for predicting overall survival and may serve as a valuable prognostic indicator for relapse and disease-free survival in NSCLC patients. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Özdede et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu